TG Therapeutics Stock (TGTX) Great Growth and Good Value in Q1 2025

TG Therapeutics (NASDAQ: TGTX) is emerging as a standout biotech stock in 2025. With its blockbuster MS drug BRIUMVI fueling surging revenue and margin expansion, the recent Q1 earnings report reflects a company hitting its stride. Despite valuations that might raise eyebrows, TGTX offers a compelling mix of rapid growth, improving fundamentals, and upside potential, making it a captivating value-growth investment in biotech’s fast lane. In this article we will dive into TG Therapeutics recent earnings, stock performance & valuation, growth potential, and the risks investor should consider.

About TG Therapeutics

Founded in 1993, TG Therapeutics is a commercial-stage biopharmaceutical company focusing on therapies for B-cell mediated diseases such as multiple sclerosis and various lymphomas. Its flagship product is BRIUMVI (ublituximab-xiiy), a monoclonal antibody designed to treat relapsing forms of MS via a convenient one-hour infusion twice annually, setting it apart from competitors. The company is also investing in subcutaneous delivery and pipeline assets, including a candidate for progressive MS.

TG Therapeutics Financial Performance

TG Therapeutics delivered an impressive financial performance in Q1 2025, underscoring its rapid growth and improving profitability. Revenue for the quarter reached $120.86 million, marking a substantial 90.4% increase from $63.47 million in Q1 2024. Earnings per share (EPS) swung into positive territory at $0.03, compared to a loss of $0.07 in the same quarter last year, a 142.86% year-over-year improvement. On a trailing twelve-month (TTM) basis, revenue climbed to $386.39 million, up 33.54% from $289.33 million in Q1 2024, while EPS decreased 15.69% to $0.24 from a TTM EPS of $0.28 in the prior year. The company’s profitability remains strong, supported by a gross profit margin of 87.43% and a net profit margin of 10.13%. Operational efficiency is reflected in a return on assets (ROA) of 7.26% and a return on equity (ROE) of 19.7%. While the debt-to-equity ratio stands at 1.07, indicating moderate leverage, TG Therapeutics is still maintaining financial stability.

Over the past five years, TG Therapeutics' revenue has been growing rapidly, with a significant boost starting in 2023 after BRIUMVI received FDA approval in 2022. Net income began to turn positive soon after, but the company is still generating negative free cash flow.

TG Therapeutics Fiscal 2025 Financial Forecast

Looking ahead, analysts forecast revenue to reach $596.09 million in 2025, representing a robust 81.18% increase from the 2024 figure of $329 million. EPS is also projected to soar to $0.84 in 2025, a 459.99% surge from $0.15 in 2024. Reflecting market optimism, analysts have given the stock a Buy rating with an average price target of $41.20, offering a potential upside of 17.16%, and a high target of $53, suggesting an upside potential of 50.69%.

TGTX Stock Price Performance and Valuation

At the time this article was written TGTX Stock was trading at $35.17. TG Therapeutics has demonstrated remarkable stock price performance over the past year, with its share price rising 109.6% significantly outperforming the S&P 500’s 8.9% gain during the same period. Over the past five years, the stock has gained 88.8%, nearly keeping pace with the S&P 500’s 93.5% increase. 

In terms of valuation, The trailing twelve-month (TTM) price-to-sales (P/S) ratio stands at 13.24 and forward P/S at 8.6. TTM price-to-earnings (P/E) ratio is a high 147.67 and the forward P/E is 41.86 which is in a reasonable level.

Based on Fiscal.ai data, if we look at the valuation since 2024, despite the strong stock price performance, the forward P/S is still around the average, while the forward P/E is significantly below the average. This indicates potential undervaluation, as BRIUMVI's sales growth remains strong.

TG Therapeutics Growth Potential

TG Therapeutics growth potential remains robust, driven by several factors.

• Strong BRIUMVI Market Position
  BRIUMVI has secured about 25% of the anti-CD20 intravenous therapy market, positioning itself as a strong competitor in multiple sclerosis treatment. TG Therapeutics aims for BRIUMVI to become the leading prescribed anti-CD20 therapy by increasing its dynamic market share. The anti-CD20 segment is expected to experience significant growth over the next decade, driven by expanding patient demand.
  Supporting this growth, long-term clinical data show that 92% of patients treated with BRIUMVI remained free from disability progression after five years, with a very low annualized relapse rate of 0.02 in year five. This sustained efficacy and durability provide BRIUMVI a competitive edge in long-term disease management, where treatment adherence and lasting effectiveness are critical for patient outcomes. These factors collectively underpin TG Therapeutics’ optimistic growth outlook for BRIUMVI.
• Pipeline Development and Innovation Investments
  TG Therapeutics is heavily investing in pipeline development to fuel future growth. In 2025, the company plans to start a pivotal program for a subcutaneous formulation of BRIUMVI, enabling self-administration with dosing at least every other month. This convenient option is expected to appeal to both patients and healthcare providers, with potential regulatory filing in early 2027 and potential approval by mid-2028.
  Additionally, TG Therapeutics is advancing azer-cel, an allogeneic CAR T-cell therapy targeting progressive multiple sclerosis. A Phase 1 trial for primary progressive MS is now open, addressing a significant unmet need with limited treatment options. The company is also optimizing BRIUMVI’s intravenous regimen by developing dosing strategies to combine initial infusions and reduce infusion times to as little as 30 minutes, improving patient convenience and treatment adherence.
• Raised 2025 Revenue Guidance
  Based on its strong first-quarter 2025 performance, TG Therapeutics raised its full-year revenue guidance significantly. The company increased its global net revenue target to approximately $575 million, up from earlier estimates of $540 million. Additionally, it raised the U.S. net revenue target for its flagship drug BRIUMVI to about $560 million, compared to the previous forecast of $525 million. This upward revision reflects growing confidence in BRIUMVI’s market demand and expanding adoption by healthcare providers.
  The company’s Q1 results included $119.7 million in U.S. BRIUMVI sales, a 137% increase year-over-year, underscoring strong commercial momentum. Management views this as a clear signal of sustained growth potential and believes BRIUMVI is well-positioned to capture increasing market share in the anti-CD20 therapy segment for multiple sclerosis

Risks to Consider

While TG Therapeutics looks like a good investment scenario, we should be mindful of potential risk.

• Market and Competitive Risks
  TG Therapeutics (TGTX) faces significant market and competitive risks in the multiple sclerosis (MS) treatment sector. Its drug BRIUMVI competes directly with well-established therapies like Roche’s Ocrevus. Maintaining and growing market share will be challenging due to strong prescriber loyalty toward existing treatments and ongoing innovation by competitors. This competitive pressure could limit TGTX’s ability to expand its presence and achieve expected sales growth in the MS market.
• Clinical and Regulatory Risks
  The success of TGTX’s pipeline, including subcutaneous BRIUMVI and azer-cel, depends on positive clinical trial outcomes and regulatory approvals. Adverse trial results, safety concerns, or delays could negatively impact stock value. For instance, BRIUMVI’s label includes warnings about infusion reactions, infections, and potential fetal harm, which could lead to regulatory scrutiny or post-marketing restrictions.
• Safety and Patient Risks
  BRIUMVI’s side effects, including infusion reactions (48% incidence) and upper respiratory infections, may discourage patients and prescribers. Rare but severe risks, such as hepatitis B reactivation or potential progressive multifocal leukoencephalopathy (PML), could result in treatment discontinuations or reputational harm for TG Therapeutics. These safety concerns may impact BRIUMVI’s adoption and market perception, potentially affecting TGTX’s growth and investor confidence in the competitive multiple sclerosis treatment landscape.

Read More: Real Brokerage Stock (REAX) Great Growth and Good Value in Q1 2025

Conclusion

In conclusion, TG Therapeutics stands out as a compelling investment opportunity in the biotech sector, driven by exceptional revenue and earnings growth, strong profitability metrics, and a promising product pipeline. With strong margins, high return on equity, and growing market share in a competitive space, TG Therapeutics offers investors a balanced mix of growth and value. Despite some risks, such as competition and execution challenges, the company’s trajectory and market potential justify a bullish outlook. For long-term investors seeking exposure to a high-growth, innovation-driven biotech, TGTX remains a strong buy candidate.